Cancell/Entelev

1. What is Cancell/Entelev?

Cancell/Entelev, also known as Sheridan’s Formula, Jim’s Juice, Crocinic Acid, JS–114, JS–101, 126–F, and Cantron, is a liquid that has been distributed as a treatment for cancer and a wide range of other diseases. Cancell/Entelev has been produced in various forms, principally by 2 manufacturers, since the late 1930s.

2. What is the history of the discovery and use of Cancell/Entelev as a complementary or alternative treatment for cancer?

Cancell/Entelev was developed in the late 1930s by a chemist, who called the mixture Entelev and provided it free to cancer patients. In 1984, another manufacturer took over the production of Entelev and distributed the mixture for free under the trademarked name Cancell to patients with cancer, acquired immunodeficiency syndrome (AIDS), and other conditions.

The 2 principal manufacturers of Cancell/Entelev have offered different explanations for the development of cancer, but their theories about how the mixture works against cancer are similar. According to the original manufacturer, Cancell/Entelev changes cancer cells so they are seen by the body as “foreign” and are destroyed. The second manufacturer states that Cancell/Entelev changes cancer cells so they “self-digest” and are replaced by normal cells. The waste material produced by this self-digestion process is eliminated through urine, perspiration, and other body fluids.

3. What is the theory behind the claim that Cancell/Entelev is useful in treating cancer?

The exact composition of Cancell/Entelev is unknown. The US Food and Drug Administration (FDA) has listed the components as inositol, nitric acid, sodium sulfite, potassium hydroxide, sulfuric acid, and catechol. The original manufacturer also identified crocinic acid as a component; however, information about the nature and origin of this chemical has not been provided, and it does not appear to be a known compound. An independent analysis of one formulation of Cancell/Entelev found 12 different compounds, none of which is known to be effective in treating any form of cancer. Refer to the PDQ summary on Cancell/Entelev for more information on theory.

4. How is Cancell/Entelev administered?

Cancell/Entelev can be administered by mouth (orally) or rectally, or it can be applied to the skin of the wrist or the ball of the foot. Cancer patients have been advised by the manufacturer to take bromelain, a digestive aid, and to avoid high intakes of vitamin C and vitamin E while using Cancell/Entelev. Proponents of Cancell state that vitamins raise the energy of the cell while Cancell lowers it.

5. Have any preclinical (laboratory or animal) studies been conducted using Cancell/Entelev?

In 1978 and 1980, the National Cancer Institute (NCI) conducted animal studies on Cancell/Entelev and determined that the mixture lacked substantial anticancer activity. Samples of Cancell/Entelev were also tested under NCI’s In Vitro (laboratory) Anticancer Drug Discovery Program in 1990 and 1991. On the basis of negative results from these studies, NCI researchers concluded that no further study of Cancell/Entelev was warranted.

The principal manufacturers of Cancell/Entelev have stated that they have performed many animal experiments with the mixture. None of these studies have been published in peer-reviewed scientific journals. No information has been provided, beyond stating that some of the experiments tested the toxicity (undesirable and harmful side effects) of Cancell/Entelev.

6. Have any clinical trials (research studies with people) been conducted using Cancell/Entelev?

No clinical trials of Cancell/Entelev have been reported. The principal manufacturers of Cancell/Entelev have stated that the mixture has been used by more than 15,000 patients and that it is safe and effective in treating 50% to 80% of all cancers. Their findings, however, have not been published in peer-reviewed, scientific journals. Only testimonials (information given by people who state that they have been helped by a particular treatment or product) or anecdotal reports (incomplete descriptions of the medical and treatment histories of one or more patients) have been made available.

7. Have any side effects or risks been reported from Cancell/Entelev?

The manufacturer states that the side effects associated with Cancell/Entelev include temporary moderate fatigue during the first few weeks of treatment. Nausea is also a reported side effect. One patient who exceeded the manufacturer’s dose recommendations experienced diarrhoea for a few hours but was reported to be fine the next day.

8. Is Cancell/Entelev approved by the FDA for use as a cancer treatment in the United States?

To conduct clinical drug research with humans in the United States, researchers must file an Investigational New Drug (IND) application with the FDA. Entelev, the original name of the mixture, was assigned an IND number by the FDA in 1982. This IND is inactive because information about the product’s composition and studies showing its therapeutic effectiveness in animals have not been submitted to the FDA. In 1989, the principal manufacturers of Cancell/Entelev were permanently prohibited from distributing the mixture, which was judged to be an unapproved new drug by the FDA. Therefore, Cancell/Entelev is not approved for use in the United States.

© Medic8 ® All Rights Reserved.